SG11201903178QA - Anti-ceacam6 antibodies and methods of use - Google Patents
Anti-ceacam6 antibodies and methods of useInfo
- Publication number
- SG11201903178QA SG11201903178QA SG11201903178QA SG11201903178QA SG11201903178QA SG 11201903178Q A SG11201903178Q A SG 11201903178QA SG 11201903178Q A SG11201903178Q A SG 11201903178QA SG 11201903178Q A SG11201903178Q A SG 11201903178QA SG 11201903178Q A SG11201903178Q A SG 11201903178QA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen
- singapore
- amino acid
- international
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201608481W | 2016-10-10 | ||
PCT/SG2017/050509 WO2018070936A1 (en) | 2016-10-10 | 2017-10-10 | Anti-ceacam6 antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903178QA true SG11201903178QA (en) | 2019-05-30 |
Family
ID=61906231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903178QA SG11201903178QA (en) | 2016-10-10 | 2017-10-10 | Anti-ceacam6 antibodies and methods of use |
Country Status (11)
Country | Link |
---|---|
US (2) | US11236160B2 (ja) |
EP (1) | EP3523333B1 (ja) |
JP (1) | JP7032412B2 (ja) |
KR (1) | KR102580319B1 (ja) |
CN (1) | CN110139874B (ja) |
AU (1) | AU2017343377A1 (ja) |
BR (1) | BR112019007272A2 (ja) |
CA (1) | CA3039886A1 (ja) |
ES (1) | ES2968264T3 (ja) |
SG (1) | SG11201903178QA (ja) |
WO (1) | WO2018070936A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019007272A2 (pt) * | 2016-10-10 | 2019-07-09 | Agency Science Tech & Res | anticorpos anti-ceacam6 e métodos de utilização |
KR102373502B1 (ko) * | 2018-05-14 | 2022-03-11 | 주식회사 금호에이치티 | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |
CN112457402B (zh) * | 2020-10-21 | 2022-08-30 | 北京纽安博生物技术有限公司 | 抗ceacam6单域抗体、人源化单域抗体及其融合蛋白和应用 |
KR20240012458A (ko) * | 2021-05-21 | 2024-01-29 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 항-ceacam5/6 항원-결합 분자 및 그의 처리 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
CA2774260C (en) * | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
EP2585476A4 (en) | 2010-06-22 | 2014-01-22 | Neogenix Oncology Inc | ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER |
CA2813133C (en) | 2010-10-01 | 2023-10-31 | National Research Council Of Canada | Anti-ceacam6 antibodies and uses thereof |
ES2625742T3 (es) * | 2012-11-20 | 2017-07-20 | Sanofi | Anticuerpos anti-CEACAM5 y usos de los mismos |
RU2739163C2 (ru) | 2015-03-23 | 2020-12-21 | Байер Фарма Акциенгезельшафт | Анти-сеасам6 антитела и их применения |
BR112019007272A2 (pt) * | 2016-10-10 | 2019-07-09 | Agency Science Tech & Res | anticorpos anti-ceacam6 e métodos de utilização |
-
2017
- 2017-10-10 BR BR112019007272A patent/BR112019007272A2/pt unknown
- 2017-10-10 CA CA3039886A patent/CA3039886A1/en active Pending
- 2017-10-10 CN CN201780073296.1A patent/CN110139874B/zh active Active
- 2017-10-10 WO PCT/SG2017/050509 patent/WO2018070936A1/en active Application Filing
- 2017-10-10 SG SG11201903178QA patent/SG11201903178QA/en unknown
- 2017-10-10 JP JP2019540505A patent/JP7032412B2/ja active Active
- 2017-10-10 EP EP17859752.2A patent/EP3523333B1/en active Active
- 2017-10-10 KR KR1020197012959A patent/KR102580319B1/ko active IP Right Grant
- 2017-10-10 AU AU2017343377A patent/AU2017343377A1/en active Pending
- 2017-10-10 US US16/341,052 patent/US11236160B2/en active Active
- 2017-10-10 ES ES17859752T patent/ES2968264T3/es active Active
-
2021
- 2021-12-22 US US17/560,232 patent/US11820821B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3039886A1 (en) | 2018-04-19 |
EP3523333B1 (en) | 2023-12-13 |
ES2968264T3 (es) | 2024-05-08 |
AU2017343377A1 (en) | 2019-05-02 |
EP3523333C0 (en) | 2023-12-13 |
BR112019007272A2 (pt) | 2019-07-09 |
EP3523333A1 (en) | 2019-08-14 |
JP2020510631A (ja) | 2020-04-09 |
KR102580319B1 (ko) | 2023-09-19 |
WO2018070936A1 (en) | 2018-04-19 |
US11820821B2 (en) | 2023-11-21 |
CN110139874B (zh) | 2023-04-14 |
US20190233514A1 (en) | 2019-08-01 |
US11236160B2 (en) | 2022-02-01 |
JP7032412B2 (ja) | 2022-03-08 |
EP3523333A4 (en) | 2020-06-10 |
KR20190075079A (ko) | 2019-06-28 |
US20220213189A1 (en) | 2022-07-07 |
CN110139874A (zh) | 2019-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903178QA (en) | Anti-ceacam6 antibodies and methods of use | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
SG11201908396PA (en) | Methods of treating tumor | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201408347UA (en) | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201901273TA (en) | Blood plasma fractions as a treatment for aging-associated cognitive disorders | |
SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity |